{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:26:39Z","timestamp":1760243199405,"version":"build-2065373602"},"reference-count":13,"publisher":"American Academy of Insurance Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Insur Med"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title\/>\n<jats:sec>\n<jats:title>Introduction.\u2014<\/jats:title>\n<jats:p>Prostate cancer is one of the most common cancers, with an approximate global annual incidence of 1.5 million men and nearly 400,000 deaths. Treatment options include surgical resection, radiotherapy, and high-intensity focused ultrasounds, often combined with hormone deprivation therapy. Insurability of prostate cancer patients is evaluated based on tumor severity using the AJCC and TNM classifications, along with PSA levels and Gleason Scores. To control the risk, life insurers use medical selection, albeit many individuals may be excluded from coverage. Regulations, such as France's \u201cRight to Be Forgotten,\u201d allow standard rate acceptance for certain prostate cancer survivors under specific conditions.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods.\u2014<\/jats:title>\n<jats:p>By matching patient data from the SEER database with mortality tables, we established a Cox survival prostate cancer model for patients sharing similar long-term survival risk and compared it with that of the general population.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results.\u2014<\/jats:title>\n<jats:p>By investigating risks in populations of various age ranges, we defined groups with variable survival risk. To distinguish insurable from uninsurable, we have defined a so-called \u201cacceptance corridor,\u201d which delimits the boundary within the expected normal range of survival for a group of age and the highest acceptable premium. This corridor is delimited with an upper boundary depicted where the risk is equal to the standard population and a lower boundary where the risk of death is higher than that of the normal population or where the risk overpasses the maximum acceptable premium of 250%.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion.\u2014<\/jats:title>\n<jats:p>In this paper, we have revisited the risk of individuals with a history of prostate cancer and have provided estimates of risk belonging within an acceptance corridor of insurability, broadening options for standard rate. This method may be further used to evaluate the impacts of regulatory guidelines, rules, and regulations, such as the right to be forgotten, to cancer patient populations.<\/jats:p>\n<\/jats:sec>","DOI":"10.17849\/insm-52-3-1-10.2","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:32:21Z","timestamp":1758241941000},"page":"116-125","source":"Crossref","is-referenced-by-count":0,"title":["Prostate Cancer Insurability: Population Identification Within the Insurability Corridor and the Right to be Forgotten"],"prefix":"10.17849","volume":"52","author":[{"given":"Antoine","family":"Moll","sequence":"first","affiliation":[{"name":"SCOR SE, 5 avenue Kl\u00e9ber, 75795 Paris cedex 16, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[{"name":"SCOR SE, 5 avenue Kl\u00e9ber, 75795 Paris cedex 16, France"},{"name":"Department of Oncology & Hematology, Groupe Hospitalier Paris Saint-Joseph, 185 Rue Raymond Losserand, 75014 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00e9o","family":"Schneider","sequence":"additional","affiliation":[{"name":"SCOR SE, 5 avenue Kl\u00e9ber, 75795 Paris cedex 16, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Vuillaume","sequence":"additional","affiliation":[{"name":"CEPS, ENS Paris-Saclay, 4 avenue des Sciences, 91190 Gif-sur-Yvette, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Li","sequence":"additional","affiliation":[{"name":"SCOR SE Beijing Branch, Level 53, China World Tower B, No.1, Jian Guo Men Wai Avenue, Beijing 100004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Charles","sequence":"additional","affiliation":[{"name":"SCOR SE, 5 avenue Kl\u00e9ber, 75795 Paris cedex 16, France"},{"name":"EconomiX - Nanterre University, 200 Av. de la R\u00e9publique Batiment G, 92000 Nanterre France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentine","family":"Sarrazin","sequence":"additional","affiliation":[{"name":"SCOR SE, 5 avenue Kl\u00e9ber, 75795 Paris cedex 16, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Plisson","sequence":"additional","affiliation":[{"name":"SCOR SE, 5 avenue Kl\u00e9ber, 75795 Paris cedex 16, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7324","reference":[{"key":"i-52-3-116-ref01","series-title":"J Natl Cancer Inst","first-page":"64","article-title":"Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening","volume":"113","author":"Jemal","year":"2021","unstructured":"Jemal A,\nCulp MB,\nMa J,\nIslami F,\nFedewa SA. Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening. J Natl Cancer Inst. 2021;113:64\u201371."},{"key":"i-52-3-116-ref02","series-title":"N Engl J Med","first-page":"1547","article-title":"Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer","volume":"388","author":"Hamdy","year":"2023","unstructured":"Hamdy FC,\nDonovan JL,\nLane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388:1547\u20131558."},{"key":"i-52-3-116-ref03","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"1970","unstructured":"Amin MB,\nEdge SB,\nGreene FL, et al. AJCC Cancer Staging Manual. New York, MD: Springer Cham; 1970."},{"key":"i-52-3-116-ref04","series-title":"Urol Clin North Am","first-page":"173","article-title":"Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database","volume":"29","author":"Stephenson","year":"2002","unstructured":"Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am. 2002;29:173\u2013181."},{"key":"i-52-3-116-ref05","series-title":"J Urol","first-page":"58","article-title":"Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging","volume":"111","author":"Gleason","year":"1974","unstructured":"Gleason DF,\nMellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58\u201364."},{"key":"i-52-3-116-ref06","series-title":"Quarterly J Economics","first-page":"488","article-title":"The Market for \u201cLemons\u201d: Quality Uncertainty and the Market Mechanism","volume":"84","author":"Akerlof","year":"1970","unstructured":"Akerlof GA. The Market for \u201cLemons\u201d: Quality Uncertainty and the Market Mechanism. Quarterly J Economics. 1970;84:488\u2013500."},{"key":"i-52-3-116-ref07","series-title":"JAMA Surg","first-page":"588","article-title":"Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database","volume":"153","author":"Doll","year":"2018","unstructured":"Doll KM,\nRademker A,\nSosa JA. Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database. JAMA Surg. 2018;153:588\u2013589."},{"key":"i-52-3-116-ref08","series-title":"Can Urol Assoc J","first-page":"121","article-title":"Pre-treatment risk stratification of prostate cancer patients: A critical review","volume":"6","author":"Rodrigues","year":"2012","unstructured":"Rodrigues G,\nWarde P,\nPickles T,\nCrook J,\nBrundage M,\nSouhami L,\nLukka H,\nGenitourinary Radiation,\nOncologists of Canada. Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J. 2012;6:121\u2013127."},{"key":"i-52-3-116-ref09","series-title":"Int J Radiat Oncol Biol Phys","first-page":"898","article-title":"Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy","volume":"53","author":"Lieberfarb","year":"2002","unstructured":"Lieberfarb ME,\nSchultz D,\nWhittington R, et al. Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53:898\u2013903."},{"key":"i-52-3-116-ref10","series-title":"J Am Statistical Assoc","first-page":"457","article-title":"Nonparametric Estimation from Incomplete Observations","volume":"53","author":"Kaplan","year":"1958","unstructured":"Kaplan EL,\nMeier P. Nonparametric Estimation from Incomplete Observations. J Am Statistical Assoc. 1958;53:457\u2013481."},{"key":"i-52-3-116-ref11","series-title":"Journal of the Royal Statistical Society: Series B (Methodological)","first-page":"187","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society: Series B (Methodological). 1972;34:187\u2013220."},{"key":"i-52-3-116-ref12","series-title":"Eur Urol Oncol","first-page":"877","article-title":"Epidemiology and Prevention of Prostate Cancer","volume":"4","author":"Gandaglia","year":"2021","unstructured":"Gandaglia G,\nLeni R,\nBray F,\nFleshner N,\nFreedland SJ,\nKibel A, et al. Epidemiology and Prevention of Prostate Cancer. Eur Urol Oncol. 2021;4:877\u2013892."},{"key":"i-52-3-116-ref13","series-title":"Nat Rev Urol","first-page":"177","article-title":"Considering the role of radical prostatectomy in 21st-century prostate cancer care","volume":"17","author":"Costello","year":"2020","unstructured":"Costello AJ. Considering the role of radical prostatectomy in 21st-century prostate cancer care. Nat Rev Urol. 2020;17:177\u2013188."}],"container-title":["Journal of Insurance Medicine"],"original-title":[],"link":[{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/52\/3\/article-p116.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/52\/3\/article-p116.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/52\/3\/article-p116.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:57:06Z","timestamp":1760144226000},"score":1,"resource":{"primary":{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/52\/3\/article-p116.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":13,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.17849\/insm-52-3-1-10.2","relation":{},"ISSN":["0743-6661"],"issn-type":[{"type":"print","value":"0743-6661"}],"subject":[],"published":{"date-parts":[[2025]]}}}